Pertento Partners LLP Has $41.23 Million Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Pertento Partners LLP raised its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 22.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,484,918 shares of the company's stock after buying an additional 646,865 shares during the quarter. Roivant Sciences comprises 3.5% of Pertento Partners LLP's portfolio, making the stock its 13th biggest position. Pertento Partners LLP owned 0.48% of Roivant Sciences worth $41,227,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. New Age Alpha Advisors LLC acquired a new position in shares of Roivant Sciences in the 4th quarter valued at $190,000. Norges Bank acquired a new stake in Roivant Sciences during the 4th quarter worth $52,443,000. WINTON GROUP Ltd grew its stake in Roivant Sciences by 1.5% in the fourth quarter. WINTON GROUP Ltd now owns 92,526 shares of the company's stock valued at $1,095,000 after acquiring an additional 1,332 shares during the period. EntryPoint Capital LLC increased its holdings in shares of Roivant Sciences by 328.3% in the fourth quarter. EntryPoint Capital LLC now owns 53,443 shares of the company's stock worth $632,000 after acquiring an additional 40,964 shares in the last quarter. Finally, United Services Automobile Association increased its holdings in shares of Roivant Sciences by 6.1% in the fourth quarter. United Services Automobile Association now owns 27,494 shares of the company's stock worth $325,000 after acquiring an additional 1,588 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

ROIV has been the subject of several research analyst reports. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $17.10.

Insiders Place Their Bets

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the transaction, the chief operating officer now owns 732,294 shares of the company's stock, valued at $8,260,276.32. The trade was a 12.01 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Rakhi Kumar sold 227,500 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the sale, the chief accounting officer now owns 163,264 shares in the company, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,395,541 shares of company stock valued at $15,028,538 in the last three months. 7.90% of the stock is currently owned by corporate insiders.

Roivant Sciences Stock Performance

Roivant Sciences stock traded up $0.17 during midday trading on Wednesday, reaching $10.02. The stock had a trading volume of 6,587,975 shares, compared to its average volume of 5,335,839. The stock has a market capitalization of $7.15 billion, a P/E ratio of -66.80 and a beta of 1.26. The firm's fifty day simple moving average is $10.69 and its 200-day simple moving average is $11.37. Roivant Sciences Ltd. has a 1-year low of $9.76 and a 1-year high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, sell-side analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.